New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 16, 2013
10:04 EDTECYT, BEAV, DX, SDLP, BFS, RPT, EVTC, AMRE, BMRN, EFC, LOCM, TPRE, KIM, DDR, RGDO, MFA, WRI, REGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AmREIT (AMRE) initiated with an Add at Capital One... BE Aerospace (BEAV) initiated with a Buy at Citigroup... DDR Corp. (DDR) initiated with an Add at Capital One... EVERTEC (EVTC) initiated with a Buy at BofA/Merrill... Endocyte (ECYT) initiated with a Buy at Brean Capital... Kimco Realty (KIM) initiated with a Strong Buy at Capital One... Ramco-Gershenson (RPT) initiated with a Neutral at Capital One... Regency Centers (REG) initiated with an Add at Capital One... Saul Centers (BFS) initiated with an Add at Capital One... Third Point Reinsurance (TPRE) initiated with a Buy at BofA/Merrill... Weingarten Realty (WRI) initiated with a Strong Buy at Capital One... Local (LOCM) initiated with a Buy at Merriman... Seadrill Partners (SDLP) coverage resumed with a Buy at Global Hunter... MFA Financial (MFA) initiated with a Buy at Compass Point... Ellington Financial (EFC) initiated with a Buy at Compass Point... Dynex Capital (DX) initiated with a Buy at Compass Point... Regado Biosciences (RGDO) initiated with an Outperform at Cowen... BioMarin (BMRN) reinstated with a Buy at BofA/Merrill.
News For AMRE;BEAV;DDR;EVTC;ECYT;KIM;RPT;REG;TPRE;BFS;WRI;LOCM;SDLP;MFA;EFC;DX;RGDO;BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
17:03 EDTDDRDDR Corp. reports Q4 FFO 32c, consensus 31c
Subscribe for More Information
February 10, 2016
16:21 EDTREGRegency Centers reports Q4 core FFO 79c, consensus 74c
Reports Q4 NAREIT FFO 67c. Reports same property NOI growth without termination fees or redevelopments 2.4%. Reports same property NOI growth without termination fees 4.2%.
February 9, 2016
07:11 EDTTPREBofa/Merrill to hold a conference
2016 Insurance Conference is being held in New York on February 9-11.
February 8, 2016
10:17 EDTBMRNSarepta approval seen as 'long shot' as FDA pushes back decision
Shares of drugmaker Sarepta Therapeutics (SRPT) took a dive in morning trading after the company said the U.S. Food and Drug Administration delayed a decision on eteplirsen for the treatment of Duchenne muscular dystrophy. WHAT'S NEW: Sarepta announced that the FDA has pushed out the the Prescription Drug User Fee Act, or PDUFA, date for eteplirsen for the treatment of Duchenne muscular dystrophy to May 26. The previous PDUFA date for the eteplirsen new drug application, or NDA, was originally set for late February. FDA POSTPONEMENT: The FDA notified Sarepta that it's submission of 4-year clinical data, including additional six minute walk test and loss of ambulation data compared to historical control, was designated as a "major amendment" to the NDA and that the PDUFA goal date was extended to allow for a full review of the submission. The FDA previously granted eteplirsen Priority Review status, as well as Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status to eteplirsen. WHAT'S NOTABLE: In late January, the FDA postponed a meeting of its advisory committee to review the Sarepta drug due to an inclement weather forecast for Washington D.C. LONG SHOT: Piper Jaffray analyst Edward Tenthoff told investors in a note that the FDA's PDUFA date postponement for eteplirsen is "not surprising" following the delay of the January 22 AdCom due to weather. Tenthoff also noted that a new AdCom has yet to be scheduled. The analyst continues to see eteplirsen accelerated approval by the new PDUFA date as a "long shot." He believes that the panel discussion will be a "plea from the community" to approve something for DMD and that members will not be asked to vote on drug approval. Tenthoff has a Neutral rating and $15 price target on Sarepta. OTHERS TO WATCH: Other companies developing treatments for Duchenne muscular dystrophy include BioMarin (BMRN) and PTC Therapeutics (PTCT). PRICE ACTION: Sarepta is down 9.5% in morning trading to $11.06.
February 5, 2016
17:05 EDTEFCEllington Financial reports estimated book value per share $22.06 as of Jan 31
Subscribe for More Information
February 3, 2016
07:04 EDTBEAVCowen to hold a forum
Subscribe for More Information
February 2, 2016
16:10 EDTKIMKimco Realty sees FY16 adjusted FFO $1.48-$1.52, consensus $1.56
Subscribe for More Information
16:09 EDTKIMKimco Realty reports Q4 adjusted FFO 37c, consensus 35c
Reports Q4 revenue $300.9M, consensus $286.56M.
08:36 EDTBMRNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
05:31 EDTBEAVBE Aerospace backs FY17 revenue growth guidance of 7.5%
Subscribe for More Information
05:29 EDTBEAVBE Aerospace raises FY6 EPS view to about $3.20 from $3.03, consensus $3.21
Subscribe for More Information
05:25 EDTBEAVBE Aerospace reports Q4 EPS 81c, consensus 81c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use